Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients

被引：0
|
作者：
Andreana De Mauri
Matteo Vidali
Doriana Chiarinotti
Giorgio Bellomo
Roberta Rolla
机构：
[1] “Maggiore della Carità” University Hospital,Nephrology and Dialysis Unit
[2] Amedeo Avogadro University of Eastern Piedmont,Department of Health Sciences
[3] “Maggiore della Carità” University Hospital,Clinical Chemistry Laboratory
来源：
Journal of Nephrology | 2019年 / 32卷
关键词：
Lipoprotein-associated phospholipase A2; Cardiovascular disease; Hemodialysis; Mortality; Atherosclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：283 / 288
页数：5
相关论文
共 50 条
  • [31] Recent Developments with Lipoprotein-Associated Phospholipase A2 Inhibitors
    Ryan J. Chauffe
    Robert L. Wilensky
    Emile R. Mohler
    Current Atherosclerosis Reports, 2010, 12 : 43 - 47
  • [32] Advantages of the lipoprotein-associated phospholipase A2 activity assay
    Donato, Leslie J.
    Meeusen, Jeffrey W.
    Callanan, Heidi
    Saenger, Amy K.
    Jaffe, Allan S.
    CLINICAL BIOCHEMISTRY, 2016, 49 (1-2) : 172 - 175
  • [33] Elevated Lipoprotein-Associated Phospholipase A2 Is Associated With Intracranial Atherosclerosis
    Wang, Yuan
    Liu, Gang
    Song, Haiqing
    Cao, Catherine
    Ji, Xunming
    Cao, Guodong
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [34] Lipoprotein-associated phospholipase A2 and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study
    T. L. Nelson
    A. Kamineni
    B. Psaty
    M. Cushman
    N. S. Jenny
    J. Hokanson
    C. Furberg
    K. J. Mukamal
    Diabetologia, 2011, 54 : 329 - 333
  • [35] Lipoprotein-associated phospholipase A2 and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study
    Nelson, T. L.
    Kamineni, A.
    Psaty, B.
    Cushman, M.
    Jenny, N. S.
    Hokanson, J.
    Furberg, C.
    Mukamal, K. J.
    DIABETOLOGIA, 2011, 54 (02) : 329 - 333
  • [36] Lipoprotein-associated phospholipase A2: A new therapeutic target
    Lonn, Eva
    CANADIAN JOURNAL OF CARDIOLOGY, 2010, 26 : 27A - 31A
  • [37] Lipoprotein-associated phospholipase A2 levels as a predictor of cardiovascular risks in patients with COPD and obstructive sleep apnea
    Badr, Eman A. E.
    Yousif, Maha
    Hazzaa, Suzan M.
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2014, 63 (02): : 405 - 410
  • [38] Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome
    Li, Jingwei
    Wang, Hong
    Tian, Junping
    Chen, Buxing
    Du, Fenghe
    MEDICINE, 2018, 97 (28)
  • [39] C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Smokers and Nonsmokers of the Ludwigshafen Risk and Cardiovascular Health Study
    Kleber, M. E.
    Siekmeier, R.
    Delgado, G.
    Grammer, T. B.
    Winkelmann, B. R.
    Scharnagl, H.
    Boehm, B. O.
    Maerz, W.
    OXIDATIVE STRESS AND CARDIORESPIRATORY FUNCTION, 2015, 832 : 15 - 23
  • [40] Lipoprotein-associated phospholipase A2:: a novel marker of cardiovascular risk and potential therapeutic target
    Macphee, C
    Benson, GM
    Shi, Y
    Zalewski, A
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (06) : 671 - 679
12345